View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 01, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Trading Symbol	FLGT
Entity Registrant Name	Fulgent Genetics, Inc.
Entity Central Index Key	0001674930
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		21,836,800
Entity File Number	001-37894
Entity Tax Identification Number	81-2621304
Entity Address, Address Line One	4978 Santa Anita Avenue
Entity Address, City or Town	Temple City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91780
City Area Code	626
Local Phone Number	350-0537
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 2,431,000	$ 11,965,000
Marketable securities	18,530,000	16,304,000
Trade accounts receivable, net of allowance for doubtful accounts of $864 and $751, as of June 30, 2020 and December 31, 2019, respectively	13,863,000	6,555,000
Other current assets	6,359,000	2,255,000
Total current assets	41,183,000	37,079,000
Marketable securities, long-term	45,403,000	41,947,000
Equity method investments	430,000	872,000
Fixed assets, net	6,013,000	5,974,000
Operating lease right-of-use asset	2,806,000	2,633,000
Other long-term assets	80,000	251,000
Total assets	95,915,000	88,756,000
Current liabilities
Accounts payable	3,636,000	1,581,000
Accrued liabilities	1,750,000	1,333,000
Income tax payable		24,000
Contract liabilities	622,000	365,000
Operating lease liabilities, short-term	501,000	420,000
Total current liabilities	6,509,000	3,723,000
Operating lease liabilities, long-term	2,363,000	2,256,000
Total liabilities	8,872,000	5,979,000
Commitments and contingencies (Note 8)
Stockholders’ equity
Common stock, $0.0001 par value per share, 50,000 shares authorized, 21,810 and 21,483 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	2,000	2,000
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding at June 30, 2020 and December 31, 2019
Additional paid-in capital	148,056,000	146,058,000
Accumulated other comprehensive income	1,049,000	146,000
Accumulated deficit	(62,064,000)	(63,429,000)
Total stockholders’ equity	87,043,000	82,777,000
Total liabilities and stockholders’ equity	$ 95,915,000	$ 88,756,000

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 864	$ 751
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	21,810,000	21,483,000
Common stock, shares outstanding	21,810,000	21,483,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue	$ 17,265	$ 8,424	$ 25,018	$ 13,794
Cost of revenue	7,717	3,620	11,774	6,588
Gross profit	9,548	4,804	13,244	7,206
Operating expenses:
Research and development	1,849	1,574	3,827	2,998
Selling and marketing	3,260	1,304	4,857	2,576
General and administrative	1,799	1,631	3,834	3,160
Total operating expenses	6,908	4,509	12,518	8,734
Operating income (loss)	2,640	295	726	(1,528)
Interest and other income, net	275	192	516	399
Income (loss) before income taxes and equity loss in investee	2,915	487	1,242	(1,129)
Provision for (benefit from) income taxes	(599)	7	(565)	20
Income (loss) before equity loss in investee	3,514	480	1,807	(1,149)
Equity loss in investee	(193)	(149)	(442)	(428)
Net income (loss)	$ 3,321	$ 331	$ 1,365	$ (1,577)
Net income (loss) per common share:
Basic	$ 0.15	$ 0.02	$ 0.06	$ (0.09)
Diluted	$ 0.14	$ 0.02	$ 0.06	$ (0.09)
Weighted-average common shares:
Basic	21,747	18,343	21,656	18,286
Diluted	22,920	19,021	22,824	18,286

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 3,321	$ 331	$ 1,365	$ (1,577)
Other comprehensive income (loss):
Foreign currency translation gain (loss)	2	(14)	(1)	1
Net unrealized gain on marketable securities, net of tax	1,240	122	904	237
Comprehensive income (loss)	$ 4,563	$ 439	$ 2,268	$ (1,339)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Stockholders' Equity	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2018	$ 51,152	$ 2	$ 114,203	$ (35)	$ (63,018)
Beginning Balance, Shares at Dec. 31, 2018		18,172,000
Equity-based compensation	583		583
Exercise of common stock options	4		4
Exercise of common stock options, Shares		9,000
Restricted stock awards, Shares		105,000
Other comprehensive gain (loss)	130			130
Net income (loss)	(1,908)				(1,908)
Ending Balance at Mar. 31, 2019	49,961	$ 2	114,790	95	(64,926)
Ending Balance, Shares at Mar. 31, 2019		18,286,000
Beginning Balance at Dec. 31, 2018	51,152	$ 2	114,203	(35)	(63,018)
Beginning Balance, Shares at Dec. 31, 2018		18,172,000
Net income (loss)	(1,577)
Ending Balance at Jun. 30, 2019	51,142	$ 2	115,532	203	(64,595)
Ending Balance, Shares at Jun. 30, 2019		18,393,000
Beginning Balance at Mar. 31, 2019	49,961	$ 2	114,790	95	(64,926)
Beginning Balance, Shares at Mar. 31, 2019		18,286,000
Equity-based compensation	737		737
Exercise of common stock options	5		5
Exercise of common stock options, Shares		15,000
Restricted stock awards, Shares		92,000
Other comprehensive gain (loss)	108			108
Net income (loss)	331				331
Ending Balance at Jun. 30, 2019	51,142	$ 2	115,532	203	(64,595)
Ending Balance, Shares at Jun. 30, 2019		18,393,000
Beginning Balance at Dec. 31, 2019	$ 82,777	$ 2	146,058	146	(63,429)
Beginning Balance, Shares at Dec. 31, 2019	21,483,000	21,483,000
Equity-based compensation	$ 924		924
Exercise of common stock options	12		12
Exercise of common stock options, Shares		33,000
Restricted stock awards, Shares		159,000
Repurchases of capital stock	(46)		(46)
Repurchases of capital stock, Shares		(3,000)
Other comprehensive gain (loss)	(339)			(339)
Net income (loss)	(1,956)				(1,956)
Ending Balance at Mar. 31, 2020	81,372	$ 2	146,948	(193)	(65,385)
Ending Balance, Shares at Mar. 31, 2020		21,672,000
Beginning Balance at Dec. 31, 2019	$ 82,777	$ 2	146,058	146	(63,429)
Beginning Balance, Shares at Dec. 31, 2019	21,483,000	21,483,000
Net income (loss)	$ 1,365
Ending Balance at Jun. 30, 2020	$ 87,043	$ 2	148,056	1,049	(62,064)
Ending Balance, Shares at Jun. 30, 2020	21,810,000	21,810,000
Beginning Balance at Mar. 31, 2020	$ 81,372	$ 2	146,948	(193)	(65,385)
Beginning Balance, Shares at Mar. 31, 2020		21,672,000
Equity-based compensation	1,080		1,080
Exercise of common stock options	28		28
Exercise of common stock options, Shares		11,000
Restricted stock awards, Shares		127,000
Other comprehensive gain (loss)	1,242			1,242
Net income (loss)	3,321				3,321
Ending Balance at Jun. 30, 2020	$ 87,043	$ 2	$ 148,056	$ 1,049	$ (62,064)
Ending Balance, Shares at Jun. 30, 2020	21,810,000	21,810,000

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flow from operating activities:
Net income (loss)	$ 1,365,000	$ (1,577,000)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Equity-based compensation	2,004,000	1,320,000
Depreciation	1,118,000	1,046,000
Noncash lease expense	220,000	201,000
Loss on disposal of fixed asset		11,000
Amortization of premium of marketable securities	218,000	44,000
Provision for bad debt	135,000
Equity loss in investee	442,000	428,000
Other	(6,000)	38,000
Changes in operating assets and liabilities:
Accounts receivable	(7,437,000)	368,000
Other current and long-term assets	(3,827,000)	183,000
Accounts payable	2,284,000	(124,000)
Accrued liabilities and other liabilities	670,000	(20,000)
Income tax payable	(24,000)
Operating lease liabilities	(205,000)	(188,000)
Net cash (used in) provided by operating activities	(3,043,000)	1,730,000
Cash flow from investing activities:
Purchases of fixed assets	(1,207,000)	(633,000)
Purchase of marketable securities	(12,387,000)	(10,178,000)
Maturities of marketable securities	7,327,000	11,500,000
Net cash (used in) provided by investing activities	(6,267,000)	689,000
Cash flow from financing activities:
Proceeds from exercise of stock options	40,000	9,000
Payment of public offering costs	(217,000)
Repurchases of capital stock	(46,000)
Net cash (used in) provided by financing activities	(223,000)	9,000
Effect of exchange rate changes on cash and cash equivalents	(1,000)	1,000
Net (decrease) increase in cash and cash equivalents	(9,534,000)	2,429,000
Cash and cash equivalents at beginning of period	11,965,000	6,736,000
Cash and cash equivalents at end of period	2,431,000	9,165,000
Supplemental disclosures of cash flow information:
Income taxes paid	28,000	20,000
Supplemental disclosures of non-cash investing and financing activities:
Purchases of fixed assets in accounts payable	497,000	$ 5,000
Operating lease right-of-use assets obtained in exchange for lease liabilities	393,000
Public offerings costs included in accounts payable	$ 2,000

Overview and Basis of Presentation

6 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Overview and Basis of Presentation

Note 1. Overview and Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. These financial statements include the assets, liabilities, revenues and expenses of all wholly-owned subsidiaries and entities in which the Company has a controlling financial interest or is deemed to be the primary beneficiary. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company uses the equity method to account for its investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. All significant intercompany accounts and transactions are eliminated from the accompanying condensed consolidated financial statements.

Nature of the Business

Fulgent Genetics, Inc., together with its subsidiaries, collectively referred to as the Company, unless otherwise noted or the context otherwise requires, is a technology company offering comprehensive genetic testing providing physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The Company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing, or NGS, with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus, or COVID-19, including NGS and reverse transcription polymerase chain reaction – based, or RT-PCR-based, tests. The Company has received Emergency Use Authorizations, or EUAs, from the U.S. Food and Drug Administration, or the FDA, for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. The Company’s at-home testing service for COVID-19 and RT-PCR-based test have been granted EUAs by the FDA only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The Company believes its test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs.

Unaudited Interim Financial Information

The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2019, which are included in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 13, 2020, or the 2019 Annual Report, and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company’s financial position and results of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or any other period. The accompanying Condensed Consolidated Balance Sheet as of December 31, 2019 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the disclosures required by U.S. GAAP. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the 2019 Annual Report, including the notes thereto.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

See the summary of the Company’s significant accounting policies set forth in the notes to its consolidated financial statements included in the 2019 Annual Report.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances, including but not limited to the potential impacts arising from the recent global pandemic related to COVID-19. As the extent and duration of the impacts from COVID-19 remain unclear, the Company’s estimates and assumptions may evolve as conditions change. Actual results could differ significantly from these estimates.

On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) accounts receivable and allowances for doubtful accounts, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities and (v) equity method investments.

Foreign Currency Translation and Foreign Currency Transactions

The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in other comprehensive income (loss) in the accompanying Condensed Consolidated Statements of Stockholders’ Equity. Gains and losses from these translations were not significant in the three and six months ended June 30, 2020 and 2019. The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and nonmonetary assets and liabilities at historical rates. Gains from these remeasurements were $26,000 in the three months ended June 30, 2020, and losses from these remeasurements were $59,000 in the six months ended June 30, 2020. Gain and losses from these remeasurements were not significant in the three and six months ended June 30, 2019.

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included as operating lease right-of-use, or ROU, assets, operating lease liabilities, short-term, and operating lease liabilities, long-term, on the Company’s Condensed Consolidated Balance Sheets.

Lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments since its leases do not provide an implicit rate. The lease ROU asset includes any base rent payments made and excludes lease incentives and variable operating expenses. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Concentration of Customers

In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. After aggregating customers that are under common control or are affiliates, one customer contributed 45% and 31%, respectively, of the Company’s revenue for the three and six months ended June 30, 2020. Two customers contributed 32% and 15%, respectively, of the Company’s revenue for the three months ended June 30, 2019, and two customers contributed 27% and 10%, respectively, of the Company’s revenue for the six months ended June 30, 2019. One customer comprised 49% of total accounts receivable as of June 30, 2020. No customer comprised 10% or more of total accounts receivable as of December 31, 2019. Revenue from the U.S. government was less than 10% of total revenue for the three and six months ended June 30, 2020 and 2019.

Revenue from Contracts with Customers

Disaggregation of Revenue

The Company classifies its customers into three payor types, Institutional, including hospitals, medical institutions, other laboratories, governmental bodies, municipalities and large corporations, Patients who pay directly or Insurance, as the Company believes this best depicts how the nature, amount, timing, and uncertainty of its revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the three and six months ended June 30, 2020 and 2019.

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
	(in thousands)
Testing Services by payor
Institutional	$	16,454	$	8,160	$	23,932	$	13,279
Patient		120		143		261		245
Insurance		691		121		825		270
Total Revenue	$	17,265	$	8,424	$	25,018	$	13,794

Contract Balances

Receivables from contracts with customers—As of June 30, 2020 and December 31, 2019, receivables from contracts with customers were approximately $13.9 million and $6.6 million, respectively, and are included within trade accounts receivable on the Condensed Consolidated Balance Sheets.

Contracts assets and liabilities —As of June 30, 2020 and December 31, 2019, contract assets from contracts with customers were $150,000, associated with contract execution and included in other current assets in the accompanying Condensed Consolidated Balance Sheets. Contract liabilities are recorded when the Company receives payment or bills prior to completing its obligation to transfer goods or services to a customer. The Company had $622,000 and $365,000 of contract liabilities as of June 30, 2020 and December 31, 2019, respectively. Revenues of $196,000 and $31,000 for the three months and $246,000 and $32,000 for the six months were recognized for the periods ended June 30, 2020 and 2019, respectively, related to contract liabilities at the beginning of the respective periods were recognized.

Transaction Price Allocated to Future Performance Obligations

The Company does not have material future obligations associated with testing services that extend beyond one year.

Recent Accounting Pronouncements

The Company evaluates all Accounting Standards Updates, or ASUs, issued by the Financial Accounting Standards Board, or FASB, for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s condensed consolidated financial statements.

ASU No. 2016-13

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU No. 2016-13 replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The update is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those reporting periods for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early application of the amendments is permitted. The Company does not expect the adoption of the new guidance under the standard to materially affect its financial position or results of operations and plans to adopt during the fiscal year 2023.

ASU No. 2018-15

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which provides new guidance on the accounting for implementation, set-up, and other upfront costs incurred in a hosted cloud computing arrangement. Under the new guidance, entities will apply the same criteria for capitalizing implementation costs as they would for an internal-use software license arrangement. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This ASU can be adopted prospectively to eligible costs incurred on or after the date of adoption or retrospectively. The adoption of this update did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.

ASU No. 2019-12

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740), which is intended to reduce the complexity of accounting standards while maintaining or enhancing the helpfulness of information provided to financial statement users. The amendment in this ASU simplifies the accounting for income taxes by removing some exceptions including the incremental approach for intraperiod tax allocation, the requirement to recognize a deferred tax liability for equity method investments, the ability not to recognize a deferred tax liability for a foreign subsidiary, and the general methodology for calculating income taxes in an interim period. Other changes include requiring entities to recognize franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate tax basis step-up in goodwill obtained in a transaction that is not a business combination, and reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, making minor codification improvements for income taxes related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method, and specifying that an entity is not required to allocate the consolidated current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements. For public business entities, this amendment is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 with early adoption permitted. The Company has decided not to early adopt the amendments. The Company is currently evaluating the amendment and has not yet determined the impact on its condensed consolidated financial statements.

Marketable Securities

6 Months Ended

Jun. 30, 2020

Investments Debt And Equity Securities [Abstract]

Marketable Securities

Note 3. Marketable Securities

The Company’s marketable securities consisted of the following:

	June 30, 2020
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	86		$	—	$	—		$	86
Corporate debt securities		18,410			124		(4	)		18,530
Less: Cash equivalents		(86	)		—		—			(86	)
Total short-term marketable securities		18,410			124		(4	)		18,530
Long-term
Corporate debt securities		43,492			908		(2	)		44,398
U.S. government agency securities		1,000			5		—			1,005
Total long-term marketable securities		44,492			913		(2	)		45,403
Total marketable securities	$	62,902		$	1,037	$	(6	)	$	63,933

	December 31, 2019
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	4,700		$	—	$	—		$	4,700
Corporate debt securities		17,962			43		(2	)		18,003
Less: Cash equivalents		(6,399	)		—		—			(6,399	)
Total short-term marketable securities		16,263			43		(2	)		16,304
Corporate debt securities		41,861			116		(30	)		41,947
Total long-term marketable securities		41,861			116		(30	)		41,947
Total marketable securities	$	58,124		$	159	$	(32	)	$	58,251

Management determined that the gross unrealized losses of $6,000 on the Company’s marketable securities as of June 30, 2020 were temporary in nature. Gross unrealized losses on the Company’s marketable securities were $32,000 as of December 31, 2019. The Company currently does not intend to sell these securities prior to maturity and does not consider these investments to be other-than-temporarily impaired as of June 30, 2020.

Fair Value Measurements

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 4. Fair Value Measurements

The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels:

Level 1:

Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.

Level 2:

Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:

Inputs are unobservable inputs for the asset or liability.

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

	June 30, 2020
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	62,928	$	—	$	62,928	$	—
U.S. government agency securities		1,005		—		1,005		—
Money market accounts		86		86		—		—
Total marketable securities and cash equivalents	$	64,019	$	86	$	63,933	$	—

	December 31, 2019
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	59,950	$	—	$	59,950	$	—
Money market accounts		4,700		4,700		—		—
Total marketable securities and cash equivalents	$	64,650	$	4,700	$	59,950	$	—

The Company’s Level 1 assets include money market instruments and are valued based upon observable market prices. Level 2 assets consist of U.S. government agency securities and corporate debt securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer quotes, bids and offers. As of June 30, 2020, the Company had no investments that were measured using unobservable (Level 3) inputs.

There were no transfers between fair value measurement levels during the three and six months ended June 30, 2020.

Gross unrealized losses for cash equivalents and marketable securities as of June 30, 2020 were not material. As of June 30, 2020, there were no unrealized losses for securities in an unrealized loss position for more than 12 months. During the six months ended June 30, 2020, the Company did not recognize other-than-temporary impairment losses related to its marketable securities.

Fixed Assets

6 Months Ended

Jun. 30, 2020

Property Plant And Equipment [Abstract]

Fixed Assets

Note 5. Fixed Assets

Major classes of fixed assets consisted of the following:

		June 30,			December 31,
	Useful Lives	2020			2019
		(in thousands)
Computer hardware	3 Years	$	1,764		$	1,705
Computer software	3 Years		541			541
Medical lab equipment	5 Years		11,163			10,493
Furniture and fixtures	5 Years		235			235
Automobile	5 Years		15			—
Leasehold improvements	Shorter of lease term or estimated useful life		916			876
Assets not yet placed in service			487			114
Total			15,121			13,964
Accumulated depreciation			(9,108	)		(7,990	)
Property and equipment, net		$	6,013		$	5,974

Depreciation expense on fixed assets totaled $549,000 and $511,000 for the three months and $1.1 million and $1.0 million for the six months ended June 30, 2020 and 2019, respectively.

Significant Balance Sheet Accounts

6 Months Ended

Jun. 30, 2020

Balance Sheet Related Disclosures [Abstract]

Significant Balance Sheet Accounts

Note 6. Significant Balance Sheet Accounts

Other current assets consisted of the following:

	June 30,		December 31,
	2020		2019
	(in thousands)
Prepaid expenses	$	2,906	$	1,288
Reagents and supplies		2,155		277
Prepaid income taxes		619		46
Marketable securities interest receivable		485		478
Contract assets		150		150
Other receivable		44		16
Total	$	6,359	$	2,255

Reagents are used for DNA sequencing applications in the Company’s DNA sequencing equipment.

Reporting Segment and Geographic Information

6 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Reporting Segment and Geographic Information

Note 7. Reporting Segment and Geographic Information

The Company views its operations and manages its business in one reporting segment. Long-lived assets were primarily located in the United States as of June 30, 2020 and December 31, 2019 with an insignificant amount located in Canada. Revenue by region during the three and six months ended June 30, 2020 and 2019 were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
	(in thousands)
Revenue:
United States	$	16,138	$	6,686	$	21,777	$	10,300
Foreign:
Canada		329		516		948		1,054
Other Countries		798		1,222		2,293		2,440
Total	$	17,265	$	8,424	$	25,018	$	13,794

Commitments and Contingencies

6 Months Ended

Jun. 30, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 8. Commitments and Contingencies

Operating Leases

See Note 9, Leases, for further information.

FF Gene Biotech

See Note 14 for a description of the Company’s commitments related to its joint venture, FF Gene Biotech (as defined in Note 14).

Purchase Obligations

As of June 30, 2020, the Company had non-cancelable purchase obligations of $9.0 million for medical lab equipment, reagents and other supplies, of which, $8.8 million is payable within twelve months, and $194,000 is payable within the next twenty-four months.

Contingencies

From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. In the opinion of management, the outcome of these matters would not have a material effect on the Company’s consolidated financial position, results of operations or cash flows.

Leases

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Leases

Note 9. Leases

The Company has various non-cancelable operating leases with varying terms through August 2023 primarily for office space. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease basis. The Company does not have any finance leases or leases with variable lease payments.

The determination of whether an arrangement contains a lease is made at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset.

The Company’s headquarters is located in Temple City, California, which is comprised of various corporate offices and a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, and licensed by the State of California Department of Public Health. Additional offices are located in El Monte, California and Atlanta, Georgia and are used for certain research and development, customer service, report generation and other administrative functions.

The Company adopted new accounting standard Accounting Standards Codification, or ASC, 842, Leases, on January 1, 2019. Upon adoption, the Company recorded ROU assets of $3.0 million and short-term and long-term lease liabilities of $384,000 and $2.6 million, respectively. The difference between the ROU asset and liability is due to the existing balance of deferred rent at the date of adoption. There was no impact to retained earnings upon adoption. The Company entered into three new operating leases, or New Leases, with an existing landlord in the three and six months ended June 30, 2020. Upon entering into the New Leases, the Company recorded ROU assets of $393,000 and short-term and long-term lease liabilities of $58,000 and $335,000, respectively. The Company also entered into four short-term leases during the three and six months ended June 30, 2020 and elected short-term lease recognition exemption for such leases.

As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available at the commencement date in determining the discount rate used to calculate present value lease payment. The Company determined its incremental borrowing rate based on inquiries with its bank. The Company’s lease agreements do not contain any residual value guarantees, material restrictive covenants, bargain purchase options or asset retirement obligations. Lease expense for the Company’s operating leases is recognized on a straight-line basis over the lease term. The Company’s leases do not contain variable lease payments.

The following was operating lease expense:

	Three months ended June 30,				Six months ended June 30,
	2020		2019		2020		2019
	(in thousands)
Operating lease cost	$	152	$	146	$	301	$	292
Short-term lease cost		3		—		3		—
Total lease cost	$	155	$	146	$	304	$	292

Supplemental cash flow information related to leases was the following:

	Three months ended June 30,				Six months ended June 30,
	2020		2019		2020		2019
	(in thousands)
Cash paid for amounts included in the measurement of lease liabilities	$	148	$	116	$	311	$	278
Noncash lease expense	$	112	$	101	$	220	$	201
Right-of-use assets obtained in exchange for new operating lease liabilities	$	393	$	—	$	393	$	—

Supplemental information related to leases was the following:

	June 30, 2020
Weighted average remaining lease term - operating leases	5.3 years
Weighted average discount rate - operating leases		5.87	%

The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:

	Operating Leases
	(in thousands)
Year Ending December 31,
2020 (remaining 6 months)	$	326
2021		662
2022		668
2023		637
2024		400
2025		387
Thereafter		262
Total lease payments		3,342
Less imputed interest		(478	)
Total	$	2,864

Equity-Based Compensation

6 Months Ended

Jun. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

Note 10. Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Condensed Consolidated Statements of Operations as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
	(in thousands)
Cost of revenue	$	270	$	167	$	501	$	309
Research and development		364		233		676		411
Selling and marketing		222		186		393		311
General and administrative		224		151		434		289
Total	$	1,080	$	737	$	2,004	$	1,320

Income Taxes

6 Months Ended

Jun. 30, 2020

Income Tax Disclosure [Abstract]

Income Taxes

Note 11. Income Taxes

Provision for income taxes consists of U.S. federal and state income taxes. A deferred tax liability is recognized for all taxable temporary differences, and a deferred tax asset is recognized for all deductible temporary differences, operating losses and tax credit carryforwards. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate for the full fiscal year ending December 31, 2020, which is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates, adjusted for discrete items recognized during the period. Certain significant or unusual items are separately recognized in the quarter during which they occur and can cause the effective tax rate to vary from quarter to quarter.

The Company’s effective tax rates were -21% and -45% for the three and six months ended June 30, 2020, respectively, compared with 1% and -2% for the three and six months ended June 30, 2019, respectively. The change in effective tax rates for the three and six months ended June 30, 2020, relative to the comparative 2019 periods, was primarily attributable to deferred tax benefit related to the partial release of valuation allowance. This partial release is related to the projected increase in taxable income attributable to the Company’s new COVID testing capabilities.

Income (Loss) per Share

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Income (Loss) per Share

Note 12. Income (Loss) per Share

The following table presents the calculation of basic and diluted income (loss) per share for the three and six months ended June 30, 2020 and 2019:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
	(in thousands, except per share data)
Net income (loss)	$	3,321	$	331	$	1,365	$	(1,577	)
Weighted-average common shares—outstanding, basic		21,747		18,343		21,656		18,286
Weighted-average common shares—outstanding, diluted		22,920		19,021		22,824		18,286
Net income (loss) per common share, basic	$	0.15	$	0.02	$	0.06	$	(0.09	)
Net income (loss) per common share, diluted	$	0.14	$	0.02	$	0.06	$	(0.09	)

The following securities have been excluded from the calculation of diluted income (loss) per share because their effect would have been anti-dilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
	(in thousands)
Options		4		19		10		387
Restricted Stock Units		42		358		21		1,093

The anti-dilutive shares described above were calculated using the treasury stock method. During the six months ended June 30, 2019, the Company had outstanding stock options and restricted stock units that were excluded from the weighted-average share calculation due to the Company’s net loss position.

Related Parties

6 Months Ended

Jun. 30, 2020

Related Parties

Note 13. Related Parties

Dr. Yun Yen, who is a member of the Company’s board of directors and a stockholder, serves as the President and Chairman of the Board for the Sino-American Cancer Foundation, or the Foundation, and served as the President for the Taipei Medical University, or the University, from August 1, 2011 through July 31, 2017 and currently serves as a Chair Professor for the University.

From time to time, the Company performs research testing services, on an arms-length basis, for the Foundation. The Company recognized zero in revenue during the three and six months ended June 30, 2020 and $2,000 for the three and six months ended June 30, 2019, as consideration for such services. Additionally, the Company subleased certain space in its facilities to the Foundation prior to April 2019. The Company recognized $8,000 and $16,000 for the three and six months ended June 30, 2019, as consideration for such sublease. As of June 30, 2020 and December 31, 2019, an insignificant amount was owed to the Company by the Foundation in connection with these relationships.

From time to time, the Company performs genetic sequencing services, on an arms-length basis, for the University. The Company recognized $17,000 and $9,000 for the three months ended and $65,000 and $22,000 for the six months ended June 30, 2020 and 2019, respectively, as consideration for such services. As of June 30, 2020, and December 31, 2019, $62,000 and $39,000, respectively, was owed to the Company by the University in connection with this relationship.

As more fully described in Note 14, in April 2017, the Company, through an affiliated company formed for the purpose of the relationship, entered into a cooperation agreement, or JV Agreement, with Xilong Scientific Co., Ltd., or Xilong Scientific, and Fuzhou Jinqiang Investment Partnership (LP), or FJIP, to form a joint venture under the laws of the People’s Republic of China, or PRC, called Fujian Fujun Gene Biotech Co., Ltd., or FF Gene Biotech. Xilong Scientific is an affiliate of Xi Long USA, Inc., a company which at one point owned greater than 10% of the Company’s common stock. XiLong USA, Inc. has since reported beneficial ownership of 4.92% of the Company’s common stock in a Schedule 13G filed with the SEC on June 12, 2020. FJIP is owned by key management of FF Gene Biotech, including Dr. Han Lin Gao, the Chief Scientific Officer and a large stockholder of the Company and the owner of approximately 25% of FJIP.

Fulgent Pharma, LLC, or Fulgent Pharma, a former subsidiary of one of the Company's subsidiaries utilizes space in the facility at which the Company’s laboratory and corporate headquarters are located. Fulgent Pharma reimburses the Company for the portion of the rent the Company pays that is attributable to the space it uses, which amounts are not significant. As of June 30, 2020, and December 31, 2019, $44,000 and $26,000, respectively, was due from Fulgent Pharma as a result of this arrangement, which is recorded in other receivable in other current assets in the accompanying Condensed Consolidated Balance Sheets.

Equity Method Investments

6 Months Ended

Jun. 30, 2020

Equity Method Investments And Joint Ventures [Abstract]

Equity Method Investments

Note 14. Equity Method Investments

In April 2017, the Company, through an affiliated company formed for the purpose of the relationship, entered into the JV Agreement with Xilong Scientific and FJIP to form FF Gene Biotech, a joint venture formed under the laws of the PRC to offer genetic testing services to customers in the PRC. Pursuant to the terms of the JV Agreement, the Company has agreed to contribute to FF Gene Biotech genetic sequencing and other equipment with a total cost of 60,000,000 renminbi, or RMB, over a five-year period for a 30% ownership interest in FF Gene Biotech, previously three-year per original agreement and amended in April 2019. Xilong Scientific has agreed to contribute to FF Gene Biotech 102,000,000 RMB over a five-year period for a 51% ownership interest in the FF Gene Biotech, previously three-year per original agreement and amended in April 2019. FJIP has agreed to contribute to FF Gene Biotech 19,000,000 RMB over a ten-year period for a 19% ownership interest in FF Gene Biotech, previously five-year per original agreement and amended in April 2019. The Company’s maximum exposure to fund losses of FF Gene Biotech as a result of its minority ownership of this entity is equal to its contribution obligation under the JV Agreement as described above. As of June 30, 2020, 39,300,000 RMB (or approximately $5.6 million U.S. dollars) remains to be contributed to the investee under the terms of the JV agreement. To date, the Company has purchased and contributed equipment with an aggregate fair value of $3.1 million pursuant to its contribution commitment under the JV Agreement. The Company accounted for this contribution in accordance with ASC 845, Nonmonetary Transactions, and recorded an investment based on the fair value of the contributed equipment, which is the same as carryover basis.

The Company concluded FF Gene Biotech is a variable interest entity as FF Gene Biotech lacks sufficient capital to operate independently. The Company concluded that it alone does not have the power to direct the most significant activities of FF Gene Biotech and therefore is not the primary beneficiary of the entity. Judgment regarding the level of influence over FF Gene Biotech includes consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions.

The Company accounts for its 30% interest in FF Gene Biotech using the equity method of accounting. The Company recorded its proportionate share of the losses of FF Gene Biotech in the three and six months ended June 30, 2020 in the accompanying Condensed Consolidated Statements of Operations, and recorded its contribution to date, net of its proportionate share in the accumulated losses of FF Gene Biotech, in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2020.

Equity method investments as of June 30, 2020 and December 31, 2019 consisted of the following:

	June 30, 2020					December 31, 2019
	Carrying Value		Ownership Percentage			Carrying Value		Ownership Percentage
	(in thousands)
FF Gene Biotech	$	430		30	%	$	872		30	%
Total equity method investments	$	430		30	%	$	872		30	%

Summary Financial Information

Summary financial information for FF Gene Biotech is as follows:

	Six Months Ended June 30
	2020			2019
Consolidated Statements of Operations Data:	(in thousands)
Net sales	$	1,602		$	1,131
Gross profit	$	28		$	579
Net loss	$	(1,618	)	$	(1,423	)
Share of loss from investments accounted for using the equity method	$	(442	)	$	(428	)

Subsequent Event

6 Months Ended

Jun. 30, 2020

Subsequent Events [Abstract]

Subsequent Event

Note 15. Subsequent Event

Subsequent to the period end, on July 23, 2020, the Company entered into an Agreement for Purchase and Sale of Property, or the Purchase Agreement, for the purchase of real property located at 4399-4401 Santa Anita Avenue, El Monte, California, or the Property, from 4401 Santa Anita Corporation, a California corporation, or the Seller, in exchange for the payment of an aggregate cash purchase price of $15.4 million. The Property consists of approximately 61,612 total square feet of building situated on 2.6 acres of land. Pursuant to the terms of the Purchase Agreement, Fulgent will have 60 days following execution of the Purchase Agreement to conduct due diligence on the Property, or the Due Diligence Period. During the Due Diligence Period, Fulgent may deliver a notice of termination to the Seller should Fulgent determine through its due diligence that the Property is not suitable for purchase by Fulgent. As set forth in and subject to the conditions of the Purchase Agreement, the closing of the sale will occur 30 days after the expiration of the Due Diligence Period.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Use of Estimates

Foreign Currency Translation and Foreign Currency Transactions

Leases

Concentration of Customers

Revenue from Contracts with Customers

Disaggregation of Revenue

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
	(in thousands)
Testing Services by payor
Institutional	$	16,454	$	8,160	$	23,932	$	13,279
Patient		120		143		261		245
Insurance		691		121		825		270
Total Revenue	$	17,265	$	8,424	$	25,018	$	13,794

Contract Balances

Transaction Price Allocated to Future Performance Obligations

The Company does not have material future obligations associated with testing services that extend beyond one year.

Recent Accounting Pronouncements

ASU No. 2016-13

ASU No. 2018-15

ASU No. 2019-12

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2020

Accounting Standards Update 2014-09

Summary of Revenue from Contracts with Customers by Payor Type

The following table summarizes revenue from contracts with customers by payor type for the three and six months ended June 30, 2020 and 2019.

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
	(in thousands)
Testing Services by payor
Institutional	$	16,454	$	8,160	$	23,932	$	13,279
Patient		120		143		261		245
Insurance		691		121		825		270
Total Revenue	$	17,265	$	8,424	$	25,018	$	13,794

Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2020

Investments Debt And Equity Securities [Abstract]

Summary of Marketable Securities

The Company’s marketable securities consisted of the following:

	June 30, 2020
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	86		$	—	$	—		$	86
Corporate debt securities		18,410			124		(4	)		18,530
Less: Cash equivalents		(86	)		—		—			(86	)
Total short-term marketable securities		18,410			124		(4	)		18,530
Long-term
Corporate debt securities		43,492			908		(2	)		44,398
U.S. government agency securities		1,000			5		—			1,005
Total long-term marketable securities		44,492			913		(2	)		45,403
Total marketable securities	$	62,902		$	1,037	$	(6	)	$	63,933

	December 31, 2019
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	4,700		$	—	$	—		$	4,700
Corporate debt securities		17,962			43		(2	)		18,003
Less: Cash equivalents		(6,399	)		—		—			(6,399	)
Total short-term marketable securities		16,263			43		(2	)		16,304
Corporate debt securities		41,861			116		(30	)		41,947
Total long-term marketable securities		41,861			116		(30	)		41,947
Total marketable securities	$	58,124		$	159	$	(32	)	$	58,251

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

	June 30, 2020
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	62,928	$	—	$	62,928	$	—
U.S. government agency securities		1,005		—		1,005		—
Money market accounts		86		86		—		—
Total marketable securities and cash equivalents	$	64,019	$	86	$	63,933	$	—

	December 31, 2019
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	59,950	$	—	$	59,950	$	—
Money market accounts		4,700		4,700		—		—
Total marketable securities and cash equivalents	$	64,650	$	4,700	$	59,950	$	—

Fixed Assets (Tables)

6 Months Ended

Jun. 30, 2020

Property Plant And Equipment [Abstract]

Major Classes of Fixed Assets

Major classes of fixed assets consisted of the following:

		June 30,			December 31,
	Useful Lives	2020			2019
		(in thousands)
Computer hardware	3 Years	$	1,764		$	1,705
Computer software	3 Years		541			541
Medical lab equipment	5 Years		11,163			10,493
Furniture and fixtures	5 Years		235			235
Automobile	5 Years		15			—
Leasehold improvements	Shorter of lease term or estimated useful life		916			876
Assets not yet placed in service			487			114
Total			15,121			13,964
Accumulated depreciation			(9,108	)		(7,990	)
Property and equipment, net		$	6,013		$	5,974

Significant Balance Sheet Accounts (Tables)

6 Months Ended

Jun. 30, 2020

Balance Sheet Related Disclosures [Abstract]

Schedule of Other Current Assets

Other current assets consisted of the following:

	June 30,		December 31,
	2020		2019
	(in thousands)
Prepaid expenses	$	2,906	$	1,288
Reagents and supplies		2,155		277
Prepaid income taxes		619		46
Marketable securities interest receivable		485		478
Contract assets		150		150
Other receivable		44		16
Total	$	6,359	$	2,255

Reporting Segment and Geographic Information (Tables)

6 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Summary of Revenue by Geographic Region

Revenue by region during the three and six months ended June 30, 2020 and 2019 were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
	(in thousands)
Revenue:
United States	$	16,138	$	6,686	$	21,777	$	10,300
Foreign:
Canada		329		516		948		1,054
Other Countries		798		1,222		2,293		2,440
Total	$	17,265	$	8,424	$	25,018	$	13,794

Leases (Tables)

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Schedule of Operating Lease Expense

The following was operating lease expense:

	Three months ended June 30,				Six months ended June 30,
	2020		2019		2020		2019
	(in thousands)
Operating lease cost	$	152	$	146	$	301	$	292
Short-term lease cost		3		—		3		—
Total lease cost	$	155	$	146	$	304	$	292

Schedule of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases was the following:

	Three months ended June 30,				Six months ended June 30,
	2020		2019		2020		2019
	(in thousands)
Cash paid for amounts included in the measurement of lease liabilities	$	148	$	116	$	311	$	278
Noncash lease expense	$	112	$	101	$	220	$	201
Right-of-use assets obtained in exchange for new operating lease liabilities	$	393	$	—	$	393	$	—

Schedule of Supplemental Information Related to Leases

Supplemental information related to leases was the following:

	June 30, 2020
Weighted average remaining lease term - operating leases	5.3 years
Weighted average discount rate - operating leases		5.87	%

Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis

The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:

	Operating Leases
	(in thousands)
Year Ending December 31,
2020 (remaining 6 months)	$	326
2021		662
2022		668
2023		637
2024		400
2025		387
Thereafter		262
Total lease payments		3,342
Less imputed interest		(478	)
Total	$	2,864

Equity-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Condensed Consolidated Statements of Operations as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
	(in thousands)
Cost of revenue	$	270	$	167	$	501	$	309
Research and development		364		233		676		411
Selling and marketing		222		186		393		311
General and administrative		224		151		434		289
Total	$	1,080	$	737	$	2,004	$	1,320

Income (Loss) per Share (Tables)

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Reconciliation of the Basic and Diluted Income (Loss) Per Share Computations

The following table presents the calculation of basic and diluted income (loss) per share for the three and six months ended June 30, 2020 and 2019:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
	(in thousands, except per share data)
Net income (loss)	$	3,321	$	331	$	1,365	$	(1,577	)
Weighted-average common shares—outstanding, basic		21,747		18,343		21,656		18,286
Weighted-average common shares—outstanding, diluted		22,920		19,021		22,824		18,286
Net income (loss) per common share, basic	$	0.15	$	0.02	$	0.06	$	(0.09	)
Net income (loss) per common share, diluted	$	0.14	$	0.02	$	0.06	$	(0.09	)

Anti-dilutive Securities Excluded from Calculation of Diluted (Income) Loss Per Share

The following securities have been excluded from the calculation of diluted income (loss) per share because their effect would have been anti-dilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
	(in thousands)
Options		4		19		10		387
Restricted Stock Units		42		358		21		1,093

Equity Method Investments (Tables)

6 Months Ended

Jun. 30, 2020

Equity Method Investments And Joint Ventures [Abstract]

Schedule of Equity Method Investments

Equity method investments as of June 30, 2020 and December 31, 2019 consisted of the following:

	June 30, 2020					December 31, 2019
	Carrying Value		Ownership Percentage			Carrying Value		Ownership Percentage
	(in thousands)
FF Gene Biotech	$	430		30	%	$	872		30	%
Total equity method investments	$	430		30	%	$	872		30	%

Summary of Financial Information for Equity Method Investees

Summary Financial Information

Summary financial information for FF Gene Biotech is as follows:

	Six Months Ended June 30
	2020			2019
Consolidated Statements of Operations Data:	(in thousands)
Net sales	$	1,602		$	1,131
Gross profit	$	28		$	579
Net loss	$	(1,618	)	$	(1,423	)
Share of loss from investments accounted for using the equity method	$	(442	)	$	(428	)

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020 USD ($) Customer	Jun. 30, 2019 USD ($) Customer	Jun. 30, 2020 USD ($) Customer	Jun. 30, 2019 USD ($) Customer	Dec. 31, 2019 USD ($) Customer
Summary Of Significant Accounting Policies [Line Items]
Foreign currency, Gains (losses) from remeasurements	$ 26,000		$ (59,000)
Receivables from contract with customers	13,863,000		13,863,000		$ 6,555,000
Contract liabilities	622,000		622,000		365,000
Contract with customer liability, revenue recognized	196,000	$ 31,000	$ 246,000	$ 32,000
Practical expedient not to disclose amount of transaction price allocated to unsatisfied performance obligations			true
Other Current Assets
Summary Of Significant Accounting Policies [Line Items]
Contract assets from contract with customers	$ 150,000		$ 150,000		$ 150,000
Customer Concentration Risk \| Revenue
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer	1	2	1	2
Customer Concentration Risk \| Revenue \| Customer One
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	45.00%	32.00%	31.00%	27.00%
Customer Concentration Risk \| Revenue \| Customer Two
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage		15.00%		10.00%
Customer Concentration Risk \| Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer			1		0
Customer Concentration Risk \| Accounts Receivable \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage					10.00%
Customer Concentration Risk \| Accounts Receivable \| Customer One
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage			49.00%

Summary of Significant Accounting Policies - Summary of Revenue from Contracts with Customers by Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	$ 17,265	$ 8,424	$ 25,018	$ 13,794
Accounting Standards Update 2014-09
Disaggregation Of Revenue [Line Items]
Type of Revenue [Extensible List]	flgt:TestingServicesMember	flgt:TestingServicesMember	flgt:TestingServicesMember	flgt:TestingServicesMember
Revenue from contracts with customers by payor type	$ 17,265	$ 8,424	$ 25,018	$ 13,794
Clinical Institutional Contracts \| Accounting Standards Update 2014-09
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	16,454	8,160	23,932	13,279
Clinical Patient Contracts \| Accounting Standards Update 2014-09
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	120	143	261	245
Clinical Insurance Contracts \| Accounting Standards Update 2014-09
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	$ 691	$ 121	$ 825	$ 270

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	$ 62,902	$ 58,124
Marketable securities, Unrealized Gains	1,037	159
Marketable securities, Unrealized Losses	(6)	(32)
Marketable securities, Aggregate Fair Value	63,933	58,251
Cash and cash equivalents	2,431	11,965
Less: Cash equivalents	(86)	(6,399)
Short-Term Marketable Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	18,410	16,263
Marketable securities, Unrealized Gains	124	43
Marketable securities, Unrealized Losses	(4)	(2)
Marketable securities, Aggregate Fair Value	18,530	16,304
Short-Term Marketable Securities \| Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	18,410	17,962
Marketable securities, Unrealized Gains	124	43
Marketable securities, Unrealized Losses	(4)	(2)
Marketable securities, Aggregate Fair Value	18,530	18,003
Long-Term Marketable Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	44,492	41,861
Marketable securities, Unrealized Gains	913	116
Marketable securities, Unrealized Losses	(2)	(30)
Marketable securities, Aggregate Fair Value	45,403	41,947
Long-Term Marketable Securities \| Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	43,492	41,861
Marketable securities, Unrealized Gains	908	116
Marketable securities, Unrealized Losses	(2)	(30)
Marketable securities, Aggregate Fair Value	44,398	41,947
Long-Term Marketable Securities \| U.S. Government Agency Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	1,000
Marketable securities, Unrealized Gains	5
Marketable securities, Aggregate Fair Value	1,005
Short Term Marketable Securities \| Money Market Accounts
Schedule Of Available For Sale Securities [Line Items]
Cash and cash equivalents	86	4,700
Cash and cash equivalents fair value disclosure	$ 86	$ 4,700

Marketable Securities - Additional Information (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Investments Debt And Equity Securities [Abstract]
Gross unrealized loss	$ 6,000	$ 32,000

Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	$ 63,933	$ 58,251
Fair Value Measurements Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	64,019	64,650
Fair Value Measurements Recurring \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	86	4,700
Fair Value Measurements Recurring \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	63,933	59,950
Fair Value Measurements Recurring \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	0	0
Fair Value Measurements Recurring \| Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	62,928	59,950
Fair Value Measurements Recurring \| Corporate Debt Securities \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	0	0
Fair Value Measurements Recurring \| Corporate Debt Securities \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	62,928	59,950
Fair Value Measurements Recurring \| Corporate Debt Securities \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	0	0
Fair Value Measurements Recurring \| U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	1,005
Fair Value Measurements Recurring \| U.S. Government Agency Securities \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	0
Fair Value Measurements Recurring \| U.S. Government Agency Securities \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	1,005
Fair Value Measurements Recurring \| U.S. Government Agency Securities \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	0
Fair Value Measurements Recurring \| Money Market Accounts
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	86	4,700
Fair Value Measurements Recurring \| Money Market Accounts \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	86	4,700
Fair Value Measurements Recurring \| Money Market Accounts \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	0	0
Fair Value Measurements Recurring \| Money Market Accounts \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	$ 0	$ 0

Fair Value Measurements - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020 USD ($)
Fair Value Disclosures [Abstract]
Fair value asset, investments measured using unobservable inputs	$ 0
Fair value assets, transfers between levels, amount	0
Unrealized losses for securities in an unrealized loss position for more than 12 months	0
Other-than-temporary impairment losses related to marketable securities	$ 0

Fixed Assets - Major Classes of Fixed Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 15,121	$ 13,964
Accumulated depreciation	(9,108)	(7,990)
Fixed assets, net	6,013	5,974
Computer Hardware
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 1,764	1,705
Useful life in years	3 years
Computer Software
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 541	541
Useful life in years	3 years
Medical Lab Equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 11,163	10,493
Useful life in years	5 years
Automobile
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 15
Useful life in years	5 years
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 235	235
Useful life in years	5 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 916	876
Useful life in years	Shorter of lease term or estimated useful life
Assets Not Yet Placed in Service
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 487	$ 114

Fixed Assets - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Depreciation expense on fixed assets	$ 549,000	$ 511,000	$ 1,118,000	$ 1,046,000

Significant Balance Sheet Accounts - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Prepaid expenses	$ 2,906	$ 1,288
Reagents and supplies	2,155	277
Prepaid income taxes	619	46
Marketable securities interest receivable	485	478
Contract assets	150	150
Other receivable	44	16
Total	$ 6,359	$ 2,255

Reporting Segment and Geographical Information - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020 Segment
Segment Reporting [Abstract]
Number of reporting segments	1

Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Revenue	$ 17,265	$ 8,424	$ 25,018	$ 13,794
United States
Segment Reporting Information [Line Items]
Revenue	16,138	6,686	21,777	10,300
Canada
Segment Reporting Information [Line Items]
Revenue	329	516	948	1,054
Other Countries
Segment Reporting Information [Line Items]
Revenue	$ 798	$ 1,222	$ 2,293	$ 2,440

Commitments and Contingencies - Additional Information (Details) - Medical Lab Equipment, Reagents and Other Supplies	Jun. 30, 2020 USD ($)
Commitments And Contingencies [Line Items]
Non-cancelable purchase obligations	$ 9,000,000
Non-cancelable purchase obligations, payable within twelve months	8,800,000
Non-cancelable purchase obligations, payable within next twenty-four months	$ 194,000

Leases - Additional Information (Details)	3 Months Ended	6 Months Ended
Leases - Additional Information (Details)	Jun. 30, 2020 USD ($) Lease	Jun. 30, 2020 USD ($) Lease	Dec. 31, 2019 USD ($)	Jan. 01, 2019 USD ($)
Lessee Lease Description [Line Items]
Operating leases term of expiration		2023-08
Operating leases, renewal term	3 years	3 years
Long-term ROU assets	$ 2,806,000	$ 2,806,000	$ 2,633,000	$ 3,000,000
Short-term lease liabilities	501,000	501,000	420,000	384,000
Long-term lease liabilities	2,363,000	2,363,000	$ 2,256,000	$ 2,600,000
New Office Space Lease
Lessee Lease Description [Line Items]
Long-term ROU assets	393,000	393,000
Short-term lease liabilities	58,000	58,000
Long-term lease liabilities	$ 335,000	$ 335,000
Number of new operating leases entered \| Lease	3	3
Number of short-term leases entered \| Lease	4	4
Accounting Standards Update 2016-02
Lessee Lease Description [Line Items]
Impact to retained earnings upon adoption of new accounting standard		$ 0

Leases - Schedule of Operating Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Operating lease cost	$ 152	$ 146	$ 301	$ 292
Short-term lease cost	3		3
Total lease cost	$ 155	$ 146	$ 304	$ 292

Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 148	$ 116	$ 311	$ 278
Noncash lease expense	112	$ 101	220	$ 201
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 393		$ 393

Leases - Schedule of Supplemental Information Related to Leases (Details)	Jun. 30, 2020
Leases [Abstract]
Weighted average remaining lease term - operating leases	5 years 3 months 18 days
Weighted average discount rate - operating leases	5.87%

Leases - Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details) $ in Thousands	Jun. 30, 2020 USD ($)
Leases [Abstract]
2020 (remaining 6 months)	$ 326
2021	662
2022	668
2023	637
2024	400
2025	387
Thereafter	262
Total lease payments	3,342
Less imputed interest	(478)
Total	$ 2,864

Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 1,080	$ 737	$ 2,004	$ 1,320
Cost of Revenue
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	270	167	501	309
Research and Development
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	364	233	676	411
Selling and Marketing
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	222	186	393	311
General and Administrative
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 224	$ 151	$ 434	$ 289

Income Taxes - Additional Information (Details)	3 Months Ended		6 Months Ended
Income Taxes - Additional Information (Details)	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Effective income tax rate	(21.00%)	1.00%	(45.00%)	(2.00%)

Income (Loss) per Share - Reconciliation of Basic and Diluted Income (Loss) Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Net income (loss)	$ 3,321	$ (1,956)	$ 331	$ (1,908)	$ 1,365	$ (1,577)
Weighted-average common shares—outstanding, basic	21,747		18,343		21,656	18,286
Weighted-average common shares—outstanding, diluted	22,920		19,021		22,824	18,286
Net income (loss) per common share, basic	$ 0.15		$ 0.02		$ 0.06	$ (0.09)
Net income (loss) per common share, diluted	$ 0.14		$ 0.02		$ 0.06	$ (0.09)

- Definition

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(20))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227

+ Details

- Definition

The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Income (Loss) per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Income (Loss) Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted loss per share	4	19	10	387
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted loss per share	42	358	21	1,093

Related Parties - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Apr. 30, 2017
Related Party Transaction [Line Items]
Ownership percentage	30.00%		30.00%		30.00%
Xilong Scientific \| Minimum
Related Party Transaction [Line Items]
Ownership percentage of common stock outstanding shares	10.00%		10.00%
Foundation
Related Party Transaction [Line Items]
Revenue from sublease		$ 8,000		$ 16,000
Foundation \| Research Testing Services
Related Party Transaction [Line Items]
Revenue from related parties	$ 0	2,000	$ 0	2,000
University \| Genetic Sequencing Services
Related Party Transaction [Line Items]
Revenue from related parties	17,000	$ 9,000	65,000	$ 22,000
Due from related parties	$ 62,000		$ 62,000		$ 39,000
FF Gene Biotech \| FJIP
Related Party Transaction [Line Items]
Ownership percentage						19.00%
FF Gene Biotech \| Dr. Han Lin Gao \| FJIP
Related Party Transaction [Line Items]
Ownership percentage	25.00%		25.00%
Beneficial Ownership \| XiLong USA
Related Party Transaction [Line Items]
Ownership percentage of common stock outstanding shares	4.92%		4.92%
Fulgent Pharma, LLC
Related Party Transaction [Line Items]
Due from related parties	$ 44,000		$ 44,000		$ 26,000

Equity Method Investments - Additional Information (Details) $ in Millions	1 Months Ended	6 Months Ended
	Apr. 30, 2017 CNY (¥)	Jun. 30, 2020 USD ($)	Jun. 30, 2020 CNY (¥)	Dec. 31, 2019
Schedule Of Equity Method Investments [Line Items]
Ownership interest to be made in joint venture		30.00%	30.00%	30.00%
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture	¥ 60,000,000
Contribution period in joint venture	5 years
Previous contribution period in joint venture	3 years
Ownership interest to be made in joint venture	30.00%	30.00%	30.00%	30.00%
Contributions remain for joint venture		$ 5.6	¥ 39,300,000
FF Gene Biotech \| Equipment
Schedule Of Equity Method Investments [Line Items]
Contributions made to joint venture \| $		$ 3.1
Xilong Scientific \| FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture	¥ 102,000,000
Contribution period in joint venture	5 years
Previous contribution period in joint venture	3 years
Ownership interest to be made in joint venture	51.00%
FJIP \| FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture	¥ 19,000,000
Contribution period in joint venture	10 years
Previous contribution period in joint venture	5 years
Ownership interest to be made in joint venture	19.00%

Equity Method Investments - Schedule of Equity Method Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Apr. 30, 2017
Schedule Of Equity Method Investments [Line Items]
Carrying Value	$ 430	$ 872
Ownership percentage	30.00%	30.00%
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Carrying Value	$ 430	$ 872
Ownership percentage	30.00%	30.00%	30.00%

Equity Method Investments - Summary of Financial Information for Equity Method Investees, Statement of Operations Data (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Schedule Of Equity Method Investments [Line Items]
Share of loss from investments accounted for using the equity method	$ (193)	$ (149)	$ (442)	$ (428)
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Net sales			1,602	1,131
Gross profit			28	579
Net loss			(1,618)	(1,423)
Share of loss from investments accounted for using the equity method			$ (442)	$ (428)

Subsequent Event- Additional Information (Details) - Subsequent Event $ in Millions	Jul. 23, 2020 USD ($) ft² a
Subsequent Event [Line Items]
Payments to aggregate cash purchase price \| $	$ 15.4
Area of property (Square feet) \| ft²	61,612
Area of land (acres) \| a	2.6
Due diligence period	60 days
Sale agreement termination date	30 days after the expiration of the Due Diligence Period.